Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer

Yonsei Medical Journal

Volumn 54, Issue 6, 2013, Pages 1394-1399

  Lee, Seung Heon ^a   Suh, In Bum ^b   Lee, Eun Joo ^c   Hur, Gyu Young ^d   Lee, Sung Yong ^d   Lee, Sang Yeub ^c   Shin, Chol ^a   Shim, Jae Jeong ^d   In, Kwang Ho ^c   Kang, Kyung Ho ^d   Yoo, Se Hwa ^c   Kim, Je Hyeong ^a  

^a Korea University   (South Korea)

^b Kangwon National University   (South Korea)

^c College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

Factor XIII; Histological type; Neoplasm staging; Non small cell lung carcinoma

Indexed keywords

BLOOD CLOTTING FACTOR 13;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD CLOTTING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROTEIN MICROARRAY; SQUAMOUS CELL CARCINOMA; THORAX RADIOGRAPHY; THROMBOPLASTIN TIME; UNDIFFERENTIATED CARCINOMA;

FACTOR XIII; HISTOLOGICAL TYPE; NEOPLASM STAGING; NON-SMALL-CELL LUNG CARCINOMA;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FACTOR XIII; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84886529771     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.6.1394     Document Type: Article

References (32)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75(1 Suppl):191-202.
3. Pastorino U. Lung cancer screening. Br J Cancer 2010;102:1681-6.
4. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-10.
5. Montuenga LM, Pio R. Current challenges in lung cancer early detection biomarkers. Eur J Cancer 2009;45 Suppl 1:377-8.
6. Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005;3:25.
7. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-8.
8. Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30:201-7.
9. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401.
10. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96: 3302-9.
11. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006;4:19-25.
12. Katona E, Nagy B, Kappelmayer J, Baktai G, Kovács L, Márialigeti T, et al. Factor XIII in bronchoalveolar lavage fluid from children with chronic bronchoalveolar inflammation. J Thromb Haemost 2005;3:1407-13.
13. Labat-Robert J. Fibronectin in malignancy. Semin Cancer Biol 2002;12:187-95.
14. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-72.
15. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer 2006;53:97-101.
16. Vairaktaris E, Vassiliou S, Yapijakis C, Spyridonidou S, Vylliotis A, Derka S, et al. Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII. Oncol Rep 2007; 18:1537-43.
17. An Y, Bekesova S, Edwards N, Goldman R. Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma. Dis Markers 2010;29:11-20.
18. Kiss F, Hevessy Z, Veszprémi A, Katona E, Kiss C, Vereb G, et al. Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A. Thromb Haemost 2006;96:176-82.
19. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15:4-9.
20. Kim SJ, Suk MH, Choi HM, Kimm KC, Jung KH, Lee SY, et al. The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea. Int J Tuberc Lung Dis 2006;10:1393-8.
21. Kwon MH, Kong DH, Jung SH, Suh IB, Kim YM, Ha KS. Rapid determination of blood coagulation factor XIII activity using protein arrays for serodiagnosis of human plasma. Anal Chem 2011; 83:2317-23.
22. Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, et al. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost 2008;6:812-9.
23. Bobek V, Kovarík J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004;58:213-9.
24. Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001;17:667-73.
25. Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Hemost 1999;25:167-72.
26. Adány R, Bárdos H. Factor XIII subunit A as an intracellular transglutaminase. Cell Mol Life Sci 2003;60:1049-60.
27. Lorand L. Factor XIII and the clotting of fibrinogen: from basic research to medicine. J Thromb Haemost 2005;3:1337-48.
28. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001;86:57-65.
29. Bárdos H, Juhász A, Répássy G, Adány R. Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 1998;80:767-72.
30. Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 2003;89:177-84.
31. Jiang WG, Ablin R, Douglas-Jones A, Mansel RE. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep 2003;10:2039-44.
32. Born P, Lippl F, Ulm K, Gerein P, Lersch C, Eckel F, et al. Reduced levels of coagulation factor XIII in patients with advanced tumor disease. Hepatogastroenterology 2000;47:194-8.